Beyond The Surface: Balancing Efficacy, Safety, And Patient Experience In Ophthalmic Delivery
By Hsiang Yun (Zoe) Chi, Independent CMC Professional
The eye is a paradox in drug delivery. It is small, accessible, and visible, and yet one of the most formidably defended organs in the human body. Anatomical gatekeeping, tear dynamics, and physiological reflexes conspire to keep foreign substances out. For CMC professionals, it is the design constraint that shapes every formulation decision from day one.
The field has spent decades trying to solve this with drops: noninvasive, self-managed, and scalable to manufacture. But the biology has never cooperated as cleanly as the clinical assumption. We are now at a point where the question is no longer how do we deliver to the eye, but which route serves this molecule, this target, and this patient. That distinction must be answered early, as everything downstream depends on it.
Efficacy: Bioavailability And the Battle Against Ocular Barriers
A topical drop encounters immediate resistance: tear turnover dilutes it within seconds, reflex blinking accelerates drainage, and the corneal epithelium resists penetration for any molecule that is not precisely lipophilic, small, and stable enough to pass. The result is ocular bioavailability typically below 5% for conventional topical formulations,1 although formulation technologies can improve exposure in selected cases. Topical ocular drug administration is adequate for many small molecules but insufficient for peptides and large biologics.
Intravitreal injection bypasses the ocular surface barriers by delivering drug directly into the vitreous cavity and enabling therapeutic exposure to posterior segment tissues that topical formulations rarely achieve. In this way, anti-VEGF biologics transformed treatment of neovascular AMD,2,3 not because the molecules were more potent in isolation but because they could finally reach the tissue of interest.
The CMC implication is significant. Injectable ocular formulations must support high concentrations within a constrained 50 to 100 µL volume, keeping in consideration viscosity, osmolality, and particle load, all of which are held to tighter windows than any topical product. Another layer to consider in development is sustained release, controlling release kinetics over weeks or months while the product remains manufacturable and injectable. Each product must also be storage stable and maintain integrity through the shear stress of injection itself.
Safety: Systemic Exposure Vs. Localized Risk
Topical administration is often assumed inherently safer than injection, an assumption that deserves scrutiny. Drops drain through the nasolacrimal duct into a highly vascularized nasopharyngeal mucosa, producing systemic absorption that can rival IV exposure for some drugs. Timolol, used in glaucoma management, has caused bradycardia and bronchospasm via this route of administration, a reminder that nasolacrimal absorption belongs in the toxicological risk assessment and not just a mention in the footnotes.
Preservative systems also carry their own burden. Benzalkonium chloride remains the most widely used ophthalmic preservative, with decades of evidence linking chronic exposure to ocular surface toxicity. These effects include tear film disruption, goblet cell loss, and, in some patients, acceleration of glaucomatous surface disease. Choosing a preservative system is not a stability decision made in isolation; it is a long-term tolerability decision affecting chronic-use patients across years of treatment.
Injection presents a different risk architecture. Systemic exposure is minimal, but localized risks, including endophthalmitis, intraocular pressure spikes, and vitreous hemorrhage, are rare but remain consequential. For manufacturing, this translates to a nonnegotiable standard: aseptic processing demands for intravitreal products are among the most stringent in parenteral manufacturing, because there is no acceptable out-of-specification result that can be retrospectively justified in a space that cannot be easily remediated.
The Patient Perspective: Compliance, Comfort, And Real-World Usability
Correct topical technique: head tilted, lid retracted, drop placed accurately, and nasolacrimal occlusion applied, is not consistently achieved even by experienced patients. This means a substantial proportion of the drops miss the eye entirely on at least some instillations. In asymptomatic chronic disease like glaucoma, this removes the feedback loop that reinforces adherence. A formulation with a 5% bioavailability ceiling, dosed incorrectly a third of the time, delivers considerably less than even its modest theoretical maximum.
Intravitreal injection imposes a different burden. The prospect of a needle in the eye generates severe enough anxiety to delay or decline treatment, particularly among older AMD patients facing indefinite monthly injections. The industry’s response has been to extend intervals as far as the molecule will support. The push is to engineer port delivery systems, long-acting implants, and high-concentration formulations for less frequent dosing, all of which are CMC challenges as much as clinical ones. These products must include stability over extended in vivo residence, predictable release kinetics, and tolerability of the device material.
Topical platforms are evolving, too. Some examples are preservative-free unit-dose and multi-dose formats. While these products reduce chronic BAK exposure while improving the experience of long-term users, the latter does require sophisticated container closure engineering to maintain sterility without chemical preservatives.
Designing For the Target
There is no universally superior route of administration. There is only the route that best serves the molecule's properties, the target tissue's location, and the patient's capacity to use the product as intended. A small molecule acting on the trabecular meshwork has different delivery logic than a biologic targeting retinal neovascularization. From a CMC perspective, designing as though both share a default answer produces formulations that are technically compliant and clinically underperforming.
The practical implication for CMC strategy is that route selection cannot be deferred to late development. Bioavailability projections, stability requirements, and patient use assumptions are all downstream of that foundational decision; teams that revisit it in Phase 2 find the cost of revision, in time, in data, in regulatory alignment, far exceeds the cost of rigor at the outset. In ophthalmic CMC, route selection is not simply a clinical choice, it defines the engineering problem that the development team must solve. Every subsequent decision, from formulation composition to stability strategy and device design, is an attempt to overcome the constraints imposed by that initial choice.
References:
- Stewart MW, Therapeutics. 2013. (Review)
- Finger RP, et al., BMC Ophthalmology. 2020.
- Dubashynskaya N, et al., Pharmaceutics. 2019. (Review)
About The Author
Hsiang Yun (Zoe) Chi is an independent CMC professional whose career spans over ten years across medical devices, small molecules, sterile products, and biologics. She began in product management within the medical device sector before transitioning into project and program management roles in pharmaceutical and biotechnology industry. Her experience includes ANDA, NDA, and BLA programs across FDA, EMA, and Asian regulatory frameworks, with hands-on expertise in formulation development, CDMO management, and CMC regulatory strategy across the U.S., European, and Asian markets. She writes on CMC strategy, drug delivery, and manufacturing science.